Gilead Ranked #4 on Fortune's 2016 "Change the World" List
Fortune has ranked Gilead 4th among 50 companies that have made an "important social or environmental impact through their profit-making strategy and operations." Criteria included measurable impact, business results and degree of innovation.
Gilead's Access Operations and Emerging Markets (AOEM) program has played a critical role in expanding access to antiretroviral therapies for patients living in developing countries. Through a model of tiered pricing and by entering into voluntary licensing agreements with generic manufacturers, Gilead has been able to scale up access to medicines in the parts of the world where they are needed most. By the end of this year, 10 million people with HIV in low-and middle-income countries will be receiving a Gilead-based HIV regimen.
"We are honored to be recognized by Fortune," said Gregg Alton, Executive Vice President, Commercial and Access Operations ALA, Corporate and Medical Affairs. "Gilead's AOEM program is a sustainable approach to reaching patients in developing countries, where access to medicines for diseases such as HIV is needed most. We are humbled to have been able to help millions of patients around the world through this program."
For more information on Fortune's 2016 "Change the World" list, please see: http://beta.fortune.com/change-the-world/list
